NCR1 and neoplasm: NK cells at the tumor site and in systemic circulation exhibited low levels of CD56 [259], activation receptors NKG2D, NKp40, NKp46, DNAM-1 [255,257,258,260,261,262,263], adaptor protein DAP12 [264] and CD16 [256], and displayed a profound reduction in cytolytic activity [258,263].